ChromaDex: Difference between revisions

ChromaDex, Inc
Company type	Public
Traded as	Nasdaq: CDXC; Russell 2000 Index component
Industry	Dietary supplements, food ingredients, chemical sample analysis
Founded	1999
Headquarters	Los Angeles, California, United States
Key people	Rob Fried; (CEO); Frank Jaksch; (Cofounder, Executive Chairman)
Products	Tru Niagen
Website	www.chromadex.com

Browse history interactively

← Previous edit

Content deleted Content added

VisualWikitext

Inline

Latest revision as of 08:17, 19 October 2024

ChromaDex is a dietary supplement and food ingredient company based in Los Angeles, California founded in 1999 that is publicly traded on the NASDAQ.

In 2011, ChromaDex licensed patents from Dartmouth College, Cornell University, and Washington University in St. Louis regarding nicotinamide riboside, which it markets and sells as an ingredient under the brand name Niagen. ChromaDex licensed patents from the University of Mississippi and the USDA to commercially develop pterostilbene and sell the compound under the brand name pTeroPure.^[1] ChromaDex no longer sells pTeroPure.^[2]

History

Founded in 1999 by Frank Jaksch, ChromaDex first acquired licensed Dartmouth patents on nicotinamide riboside in 2012, leading to the commercialization of Niagen in 2013.

ChromaDex is traded on the NASDAQ (as CDXC) as of April 2016 and was added to the U.S. Small Cap Russell 2000 Index in June 2018.

In 2017, the company acquired HealthSpan Research LLC and its product Tru Niagen, a standalone nicotinamide riboside supplement, sold direct to U.S. consumers. Also in 2017, ChromaDex raised $48 million to support research and development.

References

^ Neeb, Matthew (2011-06-20). "Ole Miss grants exclusive patent rights to ChromaDex Corp". The Daily Mississippian. Archived from the original on 2012-04-18. Retrieved 2012-05-25.
^ Krawiec, Sebastian (2018-10-31). "ChromaDex ceases new pterostilbene orders based on research demonstrating increase in LDL cholesterol". Nutritional Outlook. Retrieved 2020-05-01.

External links

Official website

[DM-1] Neeb, Matthew (2011-06-20). "Ole Miss grants exclusive patent rights to ChromaDex Corp". The Daily Mississippian. Archived from the original on 2012-04-18. Retrieved 2012-05-25.

[2] Krawiec, Sebastian (2018-10-31). "ChromaDex ceases new pterostilbene orders based on research demonstrating increase in LDL cholesterol". Nutritional Outlook. Retrieved 2020-05-01.

[1]

[2]

@@ Line 1: / Line 1: @@
+{{Short description|Food ingredient company in California}}
 {{Infobox company
 | name = ChromaDex, Inc
-| logo = ChromaDexLogo2015.png
+| logo = ChromaDex_logo.svg
 | type = [[Public company|Public]]
-| traded_as = {{NASDAQ|CDXC}}<br>[[Russell 2000 Index]] component
+| traded_as = {{NASDAQ|CDXC}}<br />[[Russell 2000 Index]] component
 | industry = [[Dietary supplements]], food ingredients, chemical sample analysis
 | foundation = 1999
 | location = [[Los Angeles, California]], United States
-| key_people = [[Rob Fried]]<br><small>(CEO)</small><br>[[Frank Jaksch]]<br><small>([[Entrepreneur|Co-Founder]], Executive Chairman)</small>
+| key_people = [[Rob Fried]]<br /><small>(CEO)</small><br />Frank Jaksch<br /><small>(Cofounder, Executive Chairman)</small>
 | products = Tru Niagen
 | website = {{URL|https://www.chromadex.com/}}
 }}
 '''ChromaDex''' is a [[dietary supplement]] and [[food ingredient]] company based in [[Los Angeles, California]] founded in 1999 that is publicly traded on the NASDAQ.
-In 2011, ChromaDex licensed patents from [[Dartmouth College]], [[Cornell University]], and [[Washington University in St. Louis]] regarding [[nicotinamide riboside]], which it markets and sells as an ingredient under the brand name Niagen and sells directly to consumers as Tru Niagen.<ref name="deathmatch">{{cite web|url=https://medium.com/neodotlife/elysium-and-basis-vs-chromadex-and-tru-niagen-10264fca0bdb|last1=Weintraub|first1=Karen|title=The Life Extension Death Match|work=NEO.LIFE}}</ref> ChromaDex licensed patents from the University of Mississippi and the [[USDA]] to commercially develop [[pterostilbene]] and sell the compound under the brand name pTeroPure.<ref name="DM">{{cite web |url=http://thedmonline.com/article/ole-miss-grants-exclusive-patent-rights-chromadex-corp |title=Ole Miss grants exclusive patent rights to ChromaDex Corp. |accessdate=2012-05-25 |last=Neeb |first=Matthew |date=2011-06-20 |work= |publisher=The Daily Mississippian |pages= |quote= |archive-url=https://web.archive.org/web/20120418075931/http://thedmonline.com/article/ole-miss-grants-exclusive-patent-rights-chromadex-corp |archive-date=2012-04-18 |url-status=dead }}</ref> ChromaDex no longer sells pTeroPure.<ref>{{Cite web|title=ChromaDex ceases new pterostilbene orders based on research demonstrating increase in LDL cholesterol|url=http://www.nutritionaloutlook.com/article/chromadex-ceases-new-pterostilbene-orders-based-research-demonstrating-increase-ldl|last=Krawiec|first=Sebastian|date=2018-10-31|website=Nutritional Outlook|language=en|access-date=2020-05-01}}</ref>
+In 2011, ChromaDex licensed patents from [[Dartmouth College]], [[Cornell University]], and [[Washington University in St. Louis]] regarding [[nicotinamide riboside]], which it markets and sells as an ingredient under the brand name Niagen. ChromaDex licensed patents from the University of Mississippi and the [[USDA]] to commercially develop [[pterostilbene]] and sell the compound under the brand name pTeroPure.<ref name="DM">{{cite web |url=http://thedmonline.com/article/ole-miss-grants-exclusive-patent-rights-chromadex-corp |title=Ole Miss grants exclusive patent rights to ChromaDex Corp. |accessdate=2012-05-25 |last=Neeb |first=Matthew |date=2011-06-20 |publisher=The Daily Mississippian |pages= |quote= |archive-url=https://web.archive.org/web/20120418075931/http://thedmonline.com/article/ole-miss-grants-exclusive-patent-rights-chromadex-corp |archive-date=2012-04-18 |url-status=dead }}</ref> ChromaDex no longer sells pTeroPure.<ref>{{Cite web|title=ChromaDex ceases new pterostilbene orders based on research demonstrating increase in LDL cholesterol|url=http://www.nutritionaloutlook.com/article/chromadex-ceases-new-pterostilbene-orders-based-research-demonstrating-increase-ldl|last=Krawiec|first=Sebastian|date=2018-10-31|website=Nutritional Outlook|language=en|access-date=2020-05-01}}</ref>
-ChromaDex also licensed patents from the University of Mississippi on Immulina, a proprietary extract of ''Arthrospira platensis'' (or spirulina, a type of algae) which it continues to sell today as an ingredient for use in dietary supplements.
 == History ==
@@ Line 23: / Line 23: @@
 ChromaDex is traded on the NASDAQ (as CDXC) as of April 2016 and was added to the U.S. Small Cap Russell 2000 Index in June 2018.
-In 2017, the company acquired HealthSpan Research LLC and its product Tru Niagen, a standalone nicotinamide riboside supplement, sold direct to U.S. consumers. Also in 2017, ChromaDex raised $48 million, led by Horizons Ventures, the investment firm of Hong Kong billionaire Li Ka-Shing, as well as venture capitalists and strategic investors, including ICONIQ Capital, to support research and development, and global expansion.
+In 2017, the company acquired HealthSpan Research LLC and its product Tru Niagen, a standalone nicotinamide riboside supplement, sold direct to U.S. consumers. Also in 2017, ChromaDex raised $48 million to support research and development.
-== Niagen clinical studies ==
-Niagen, the active ingredient in Tru Niagen, is the only patented form of nicotinamide riboside that has been extensively studied in published human clinical trials.<ref name=":0">{{Cite journal |last=Trammell |first=Samuel A. J. |last2=Schmidt |first2=Mark S. |last3=Weidemann |first3=Benjamin J. |last4=Redpath |first4=Philip |last5=Jaksch |first5=Frank |last6=Dellinger |first6=Ryan W. |last7=Li |first7=Zhonggang |last8=Abel |first8=E. Dale |last9=Migaud |first9=Marie E. |last10=Brenner |first10=Charles |date=2016-10-10 |title=Nicotinamide riboside is uniquely and orally bioavailable in mice and humans |url=https://www.nature.com/articles/ncomms12948 |journal=Nature Communications |language=en |volume=7 |issue=1 |pages=12948 |doi=10.1038/ncomms12948 |issn=2041-1723 |pmc=5062546 |pmid=27721479}}</ref><ref name=":1">{{Cite journal |last=Airhart |first=Sophia E. |last2=Shireman |first2=Laura M. |last3=Risler |first3=Linda J. |last4=Anderson |first4=Gail D. |last5=Gowda |first5=G. A. Nagana |last6=Raftery |first6=Daniel |last7=Tian |first7=Rong |last8=Shen |first8=Danny D. |last9=O’Brien |first9=Kevin D. |date=2017-12-06 |title=An open-label, non-randomized study of the pharmacokinetics of the nutritional supplement nicotinamide riboside (NR) and its effects on blood NAD+ levels in healthy volunteers |url=https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0186459 |journal=PLOS ONE |language=en |volume=12 |issue=12 |pages=e0186459 |doi=10.1371/journal.pone.0186459 |issn=1932-6203 |pmc=5718430 |pmid=29211728}}</ref><ref name=":2">{{Cite journal |last=Martens |first=Christopher R. |last2=Denman |first2=Blair A. |last3=Mazzo |first3=Melissa R. |last4=Armstrong |first4=Michael L. |last5=Reisdorph |first5=Nichole |last6=McQueen |first6=Matthew B. |last7=Chonchol |first7=Michel |last8=Seals |first8=Douglas R. |date=2018-03-29 |title=Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults |url=https://www.nature.com/articles/s41467-018-03421-7 |journal=Nature Communications |language=en |volume=9 |issue=1 |pages=1286 |doi=10.1038/s41467-018-03421-7 |issn=2041-1723 |pmc=5876407 |pmid=29599478}}</ref><ref name=":3">{{Cite journal |last=Dollerup |first=Ole L |last2=Christensen |first2=Britt |last3=Svart |first3=Mads |last4=Schmidt |first4=Mark S |last5=Sulek |first5=Karolina |last6=Ringgaard |first6=Steffen |last7=Stødkilde-Jørgensen |first7=Hans |last8=Møller |first8=Niels |last9=Brenner |first9=Charles |last10=Treebak |first10=Jonas T |last11=Jessen |first11=Niels |date=2018-08-01 |title=A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects |url=https://www.sciencedirect.com/science/article/pii/S0002916522029409 |journal=The American Journal of Clinical Nutrition |language=en |volume=108 |issue=2 |pages=343–353 |doi=10.1093/ajcn/nqy132 |issn=0002-9165}}</ref><ref name=":4">{{Cite journal |last=Conze |first=Dietrich |last2=Brenner |first2=Charles |last3=Kruger |first3=Claire L. |date=2019-07-05 |title=Safety and Metabolism of Long-term Administration of Niagen (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults |url=https://www.nature.com/articles/s41598-019-46120-z |journal=Scientific Reports |language=en |volume=9 |issue=1 |pages=9772 |doi=10.1038/s41598-019-46120-z |issn=2045-2322 |pmc=6611812 |pmid=31278280}}</ref><ref name=":5">{{Cite journal |last=Elhassan |first=Yasir S. |last2=Kluckova |first2=Katarina |last3=Fletcher |first3=Rachel S. |last4=Schmidt |first4=Mark S. |last5=Garten |first5=Antje |last6=Doig |first6=Craig L. |last7=Cartwright |first7=David M. |last8=Oakey |first8=Lucy |last9=Burley |first9=Claire V. |last10=Jenkinson |first10=Ned |last11=Wilson |first11=Martin |last12=Lucas |first12=Samuel J. E. |last13=Akerman |first13=Ildem |last14=Seabright |first14=Alex |last15=Lai |first15=Yu-Chiang |date=2019-08-13 |title=Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD+ Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures |url=https://www.cell.com/cell-reports/abstract/S2211-1247(19)30940-4 |journal=Cell Reports |language=English |volume=28 |issue=7 |pages=1717–1728.e6 |doi=10.1016/j.celrep.2019.07.043 |issn=2211-1247 |pmc=6702140 |pmid=31412242}}</ref><ref name=":6">{{Cite journal |last=Dollerup |first=Ole L |last2=Trammell |first2=Samuel A J |last3=Hartmann |first3=Bolette |last4=Holst |first4=Jens J |last5=Christensen |first5=Britt |last6=Møller |first6=Niels |last7=Gillum |first7=Matthew P |last8=Treebak |first8=Jonas T |last9=Jessen |first9=Niels |date=2019-11-01 |title=Effects of Nicotinamide Riboside on Endocrine Pancreatic Function and Incretin Hormones in Nondiabetic Men With Obesity |url=https://academic.oup.com/jcem/article/104/11/5703/5544497 |journal=The Journal of Clinical Endocrinology & Metabolism |language=en |volume=104 |issue=11 |pages=5703–5714 |doi=10.1210/jc.2019-01081 |issn=0021-972X}}</ref><ref name=":7">{{Cite journal |last=Dollerup |first=Ole L. |last2=Chubanava |first2=Sabina |last3=Agerholm |first3=Marianne |last4=Søndergård |first4=Stine D. |last5=Altıntaş |first5=Ali |last6=Møller |first6=Andreas B. |last7=Høyer |first7=Kasper F. |last8=Ringgaard |first8=Steffen |last9=Stødkilde‐Jørgensen |first9=Hans |last10=Lavery |first10=Gareth G. |last11=Barrès |first11=Romain |last12=Larsen |first12=Steen |last13=Prats |first13=Clara |last14=Jessen |first14=Niels |last15=Treebak |first15=Jonas T. |date= |title=Nicotinamide riboside does not alter mitochondrial respiration, content or morphology in skeletal muscle from obese and insulin‐resistant men |url=https://onlinelibrary.wiley.com/doi/10.1113/JP278752 |journal=The Journal of Physiology |language=en |volume=598 |issue=4 |pages=731–754 |doi=10.1113/JP278752 |issn=0022-3751}}</ref><ref name=":8">{{Cite journal |last=Remie |first=Carlijn ME |last2=Roumans |first2=Kay HM |last3=Moonen |first3=Michiel PB |last4=Connell |first4=Niels J |last5=Havekes |first5=Bas |last6=Mevenkamp |first6=Julian |last7=Lindeboom |first7=Lucas |last8=de Wit |first8=Vera HW |last9=van de Weijer |first9=Tineke |last10=Aarts |first10=Suzanne ABM |last11=Lutgens |first11=Esther |last12=Schomakers |first12=Bauke V |last13=Elfrink |first13=Hyung L |last14=Zapata-Pérez |first14=Rubén |last15=Houtkooper |first15=Riekelt H |date=2020-08-01 |title=Nicotinamide riboside supplementation alters body composition and skeletal muscle acetylcarnitine concentrations in healthy obese humans |url=https://www.sciencedirect.com/science/article/pii/S0002916522008103 |journal=The American Journal of Clinical Nutrition |language=en |volume=112 |issue=2 |pages=413–426 |doi=10.1093/ajcn/nqaa072 |issn=0002-9165 |pmc=7398770 |pmid=32320006}}</ref><ref name=":9">{{Cite journal |last=Zhang |first=Cheng |last2=Bjornson |first2=Elias |last3=Arif |first3=Muhammad |last4=Tebani |first4=Abdellah |last5=Lovric |first5=Alen |last6=Benfeitas |first6=Rui |last7=Ozcan |first7=Mehmet |last8=Juszczak |first8=Kajetan |last9=Kim |first9=Woonghee |last10=Kim |first10=Jung Tae |last11=Bidkhori |first11=Gholamreza |last12=Ståhlman |first12=Marcus |last13=Bergh |first13=Per‐Olof |last14=Adiels |first14=Martin |last15=Turkez |first15=Hasan |date= |title=The acute effect of metabolic cofactor supplementation: a potential therapeutic strategy against non‐alcoholic fatty liver disease |url=https://onlinelibrary.wiley.com/doi/10.15252/msb.209495 |journal=Molecular Systems Biology |language=en |volume=16 |issue=4 |doi=10.15252/msb.209495 |issn=1744-4292 |pmc=7184219 |pmid=32337855}}</ref><ref>{{Cite journal |last=Zhou |first=Bo |last2=Wang |first2=Dennis Ding-Hwa |last3=Qiu |first3=Yanhua |last4=Airhart |first4=Sophia |last5=Liu |first5=Yaxin |last6=Stempien-Otero |first6=April |last7=O’Brien |first7=Kevin D. |last8=Tian |first8=Rong |date=2020-11-02 |title=Boosting NAD level suppresses inflammatory activation of PBMCs in heart failure |url=https://www.jci.org/articles/view/138538 |journal=The Journal of Clinical Investigation |language=en |volume=130 |issue=11 |pages=6054–6063 |doi=10.1172/JCI138538 |issn=0021-9738 |pmc=7598081 |pmid=32790648}}</ref><ref>{{Cite journal |last=Tinnevelt |first=Gerjen H. |last2=Engelke |first2=Udo F. H. |last3=Wevers |first3=Ron A. |last4=Veenhuis |first4=Stefanie |last5=Willemsen |first5=Michel A. |last6=Coene |first6=Karlien L. M. |last7=Kulkarni |first7=Purva |last8=Jansen |first8=Jeroen J. |date= |title=Variable Selection in Untargeted Metabolomics and the Danger of Sparsity |url=https://www.mdpi.com/2218-1989/10/11/470 |journal=Metabolites |language=en |volume=10 |issue=11 |pages=470 |doi=10.3390/metabo10110470 |issn=2218-1989 |pmc=7698561 |pmid=33213095}}</ref><ref>{{Cite journal |last=Nascimento |first=Emmani B M |last2=Moonen |first2=Michiel P B |last3=Remie |first3=Carlijn M E |last4=Gariani |first4=Karim |last5=Jörgensen |first5=Johanna A |last6=Schaart |first6=Gert |last7=Hoeks |first7=Joris |last8=Auwerx |first8=Johan |last9=van Marken Lichtenbelt |first9=Wouter D |last10=Schrauwen |first10=Patrick |date=2021-04-23 |title=Nicotinamide Riboside Enhances In Vitro Beta-adrenergic Brown Adipose Tissue Activity in Humans |url=https://academic.oup.com/jcem/article/106/5/1437/6125711 |journal=The Journal of Clinical Endocrinology & Metabolism |language=en |volume=106 |issue=5 |pages=1437–1447 |doi=10.1210/clinem/dgaa960 |issn=0021-972X}}</ref><ref>{{Cite journal |last=Li |first=Dong-Jie |last2=Sun |first2=Si-Jia |last3=Fu |first3=Jiang-Tao |last4=Ouyang |first4=Shen-Xi |last5=Zhao |first5=Qin-Jie |last6=Su |first6=Li |last7=Ji |first7=Qing-Xi |last8=Sun |first8=Di-Ynag |last9=Zhu |first9=Jia-Hui |last10=Zhang |first10=Guo-Yan |last11=Ma |first11=Jia-Wei |last12=Lan |first12=Xiu-Ting |last13=Zhao |first13=Yi |last14=Tong |first14=Jie |last15=Li |first15=Guo-Qiang |date=2021-02-25 |title=NAD+-boosting therapy alleviates nonalcoholic fatty liver disease via stimulating a novel exerkine Fndc5/irisin |url=https://www.thno.org/v11p4381.htm |journal=Theranostics |language=en |volume=11 |issue=9 |pages=4381–4402 |doi=10.7150/thno.53652 |issn=1838-7640 |pmc=7977447 |pmid=33754067}}</ref><ref>{{Cite journal |last=Altay |first=Ozlem |last2=Arif |first2=Muhammad |last3=Li |first3=Xiangyu |last4=Yang |first4=Hong |last5=Aydın |first5=Mehtap |last6=Alkurt |first6=Gizem |last7=Kim |first7=Woonghee |last8=Akyol |first8=Dogukan |last9=Zhang |first9=Cheng |last10=Dinler‐Doganay |first10=Gizem |last11=Turkez |first11=Hasan |last12=Shoaie |first12=Saeed |last13=Nielsen |first13=Jens |last14=Borén |first14=Jan |last15=Olmuscelik |first15=Oktay |date= |title=Combined Metabolic Activators Accelerates Recovery in Mild‐to‐Moderate COVID‐19 |url=https://onlinelibrary.wiley.com/doi/10.1002/advs.202101222 |journal=Advanced Science |language=en |volume=8 |issue=17 |pages=2101222 |doi=10.1002/advs.202101222 |issn=2198-3844 |pmc=8420376 |pmid=34180141}}</ref><ref>{{Cite journal |last=Stocks |first=Ben |last2=Ashcroft |first2=Stephen P. |last3=Joanisse |first3=Sophie |last4=Dansereau |first4=Linda C. |last5=Koay |first5=Yen Chin |last6=Elhassan |first6=Yasir S. |last7=Lavery |first7=Gareth G. |last8=Quek |first8=Lake‐Ee |last9=O'Sullivan |first9=John F. |last10=Philp |first10=Ashleigh M. |last11=Wallis |first11=Gareth A. |last12=Philp |first12=Andrew |date= |title=Nicotinamide riboside supplementation does not alter whole‐body or skeletal muscle metabolic responses to a single bout of endurance exercise |url=https://onlinelibrary.wiley.com/doi/10.1113/JP280825 |journal=The Journal of Physiology |language=en |volume=599 |issue=5 |pages=1513–1531 |doi=10.1113/JP280825 |issn=0022-3751}}</ref><ref>{{Cite journal |last=Veenhuis |first=Stefanie J.G. |last2=Os |first2=Nienke J.H. |last3=Janssen |first3=Anjo J.W.M. |last4=Gerven |first4=Marjo H.J.C. |last5=Coene |first5=Karlien L.M. |last6=Engelke |first6=Udo. F.H. |last7=Wevers |first7=Ron A. |last8=Tinnevelt |first8=Gerjen H. |last9=Heine |first9=Rob |last10=Warrenburg |first10=Bart P.C. |last11=Weemaes |first11=Corry M.R. |last12=Roeleveld |first12=Nel |last13=Willemsen |first13=Michèl A.A.P. |date= |title=Nicotinamide Riboside Improves Ataxia Scores and Immunoglobulin Levels in Ataxia Telangiectasia |url=https://onlinelibrary.wiley.com/doi/10.1002/mds.28788 |journal=Movement Disorders |language=en |volume=36 |issue=12 |pages=2951–2957 |doi=10.1002/mds.28788 |issn=0885-3185 |pmc=9291897 |pmid=34515380}}</ref><ref name=":10">{{Cite journal |last=Zeybel |first=Mujdat |last2=Altay |first2=Ozlem |last3=Arif |first3=Muhammad |last4=Li |first4=Xiangyu |last5=Yang |first5=Hong |last6=Fredolini |first6=Claudia |last7=Akyildiz |first7=Murat |last8=Saglam |first8=Burcin |last9=Gonenli |first9=Mehmet Gokhan |last10=Ural |first10=Dilek |last11=Kim |first11=Woonghee |last12=Schwenk |first12=Jochen M |last13=Zhang |first13=Cheng |last14=Shoaie |first14=Saeed |last15=Nielsen |first15=Jens |date= |title=Combined metabolic activators therapy ameliorates liver fat in nonalcoholic fatty liver disease patients |url=https://onlinelibrary.wiley.com/doi/10.15252/msb.202110459 |journal=Molecular Systems Biology |language=en |volume=17 |issue=10 |doi=10.15252/msb.202110459 |issn=1744-4292 |pmc=8724764 |pmid=34694070}}</ref><ref name=":11">{{Cite journal |last=Wu |first=Jing |last2=Singh |first2=Komudi |last3=Lin |first3=Amy |last4=Meadows |first4=Allison M. |last5=Wu |first5=Kaiyuan |last6=Shing |first6=Vivian |last7=Bley |first7=Maximilian |last8=Hassanzadeh |first8=Shahin |last9=Huffstutler |first9=Rebecca D. |last10=Schmidt |first10=Mark S. |last11=Blanco |first11=Luz P. |last12=Tian |first12=Rong |last13=Brenner |first13=Charles |last14=Pirooznia |first14=Mehdi |last15=Kaplan |first15=Mariana J. |date=2022-03-01 |title=Boosting NAD+ blunts TLR4-induced type I IFN in control and systemic lupus erythematosus monocytes |url=https://www.jci.org/articles/view/139828 |journal=The Journal of Clinical Investigation |language=en |volume=132 |issue=5 |doi=10.1172/JCI139828 |issn=0021-9738 |pmc=8884917 |pmid=35025762}}</ref><ref>{{Cite journal |last=Brakedal |first=Brage |last2=Dölle |first2=Christian |last3=Riemer |first3=Frank |last4=Ma |first4=Yilong |last5=Nido |first5=Gonzalo S. |last6=Skeie |first6=Geir Olve |last7=Craven |first7=Alexander R. |last8=Schwarzlmüller |first8=Thomas |last9=Brekke |first9=Njål |last10=Diab |first10=Joseph |last11=Sverkeli |first11=Lars |last12=Skjeie |first12=Vivian |last13=Varhaug |first13=Kristin |last14=Tysnes |first14=Ole-Bjørn |last15=Peng |first15=Shichun |date=2022-03-01 |title=The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s disease |url=https://www.cell.com/cell-metabolism/abstract/S1550-4131(22)00045-6 |journal=Cell Metabolism |language=English |volume=34 |issue=3 |pages=396–407.e6 |doi=10.1016/j.cmet.2022.02.001 |issn=1550-4131 |pmid=35235774}}</ref><ref name=":12">{{Cite journal |last=Wang |first=Dennis D. |last2=Airhart |first2=Sophia E. |last3=Zhou |first3=Bo |last4=Shireman |first4=Laura M. |last5=Jiang |first5=Siyi |last6=Melendez Rodriguez |first6=Carolina |last7=Kirkpatrick |first7=James N. |last8=Shen |first8=Danny D. |last9=Tian |first9=Rong |last10=O’Brien |first10=Kevin D. |date=2022-12-01 |title=Safety and Tolerability of Nicotinamide Riboside in Heart Failure with Reduced Ejection Fraction |url=https://www.sciencedirect.com/science/article/pii/S2452302X22002327 |journal=JACC: Basic to Translational Science |language=en |volume=7 |issue=12 |pages=1183–1196 |doi=10.1016/j.jacbts.2022.06.012 |issn=2452-302X |pmc=9831861 |pmid=36644285}}</ref><ref>{{Cite journal |last=Vreones |first=Michael |last2=Mustapic |first2=Maja |last3=Moaddel |first3=Ruin |last4=Pucha |first4=Krishna A. |last5=Lovett |first5=Jacqueline |last6=Seals |first6=Douglas R. |last7=Kapogiannis |first7=Dimitrios |last8=Martens |first8=Christopher R. |date= |title=Oral nicotinamide riboside raises NAD + and lowers biomarkers of neurodegenerative pathology in plasma extracellular vesicles enriched for neuronal origin |url=https://onlinelibrary.wiley.com/doi/10.1111/acel.13754 |journal=Aging Cell |language=en |volume=22 |issue=1 |doi=10.1111/acel.13754 |issn=1474-9718 |pmc=9835564 |pmid=36515353}}</ref><ref>{{Cite journal |last=Lapatto |first=Helena A.K. |last2=Kuusela |first2=Minna |last3=Heikkinen |first3=Aino |last4=Muniandy |first4=Maheswary |last5=van der Kolk |first5=Birgitta W. |last6=Gopalakrishnan |first6=Swetha |last7=Pöllänen |first7=Noora |last8=Sandvik |first8=Martin |last9=Schmidt |first9=Mark S. |last10=Heinonen |first10=Sini |last11=Saari |first11=Sina |last12=Kuula |first12=Juho |last13=Hakkarainen |first13=Antti |last14=Tampio |first14=Janne |last15=Saarinen |first15=Tuure |date=2023-01-13 |title=Nicotinamide riboside improves muscle mitochondrial biogenesis, satellite cell differentiation, and gut microbiota in a twin study |url=https://www.science.org/doi/10.1126/sciadv.add5163 |journal=Science Advances |language=en |volume=9 |issue=2 |pages=eadd5163 |doi=10.1126/sciadv.add5163 |issn=2375-2548 |pmc=9839336 |pmid=36638183}}</ref><ref>{{Cite journal |last=Yulug |first=Burak |last2=Altay |first2=Ozlem |last3=Li |first3=Xiangyu |last4=Hanoglu |first4=Lutfu |last5=Cankaya |first5=Seyda |last6=Lam |first6=Simon |last7=Velioglu |first7=Halil Aziz |last8=Yang |first8=Hong |last9=Coskun |first9=Ebru |last10=Idil |first10=Ezgi |last11=Nogaylar |first11=Rahim |last12=Ozsimsek |first12=Ahmet |last13=Bayram |first13=Cemil |last14=Bolat |first14=Ismail |last15=Oner |first15=Sena |date=2023-01-26 |title=Combined metabolic activators improve cognitive functions in Alzheimer’s disease patients: a randomised, double-blinded, placebo-controlled phase-II trial |url=https://doi.org/10.1186/s40035-023-00336-2 |journal=Translational Neurodegeneration |volume=12 |issue=1 |pages=4 |doi=10.1186/s40035-023-00336-2 |issn=2047-9158 |pmc=9879258 |pmid=36703196}}</ref>
-Thirteen peer-reviewed clinical studies using Niagen have been published in high-tiered biomedical journals, demonstrating an increase in NAD+*.<ref name=":0" /><ref name=":1" /><ref name=":2" /><ref name=":3" /><ref name=":4" /><ref name=":5" /><ref name=":6" /><ref name=":7" /><ref name=":8" /><ref name=":9" /><ref name=":10" /><ref name=":11" /><ref name=":12" /> These 13 clinical studies include the first clinical trials supporting the bioavailability, safety, efficacy, pharmacokinetics, dose-response effect on blood NAD+ levels in humans, as well as its health benefits, including improvements in cardiovascular health, liver health, body composition, and mitochondrial function.
-Additional studies in humans are ongoing or have recently completed (as of December 2022). More specifically, an additional 40+ completed or ongoing clinical trials investigating nicotinamide riboside only are currently registered on www.clinicaltrials.gov.
-== Research initiatives ==
-The [https://www.chromadex.com/research/cerp/ ChromaDex External Research Program (CERP <sup>TM</sup>)] is setting the industry standard for excellence in collaborative research on NAD+. Through CERP , ChromaDex partners with independent,third-party leading universities and research institutions worldwide and upon request, donates Niagen, one of the most studied and efficient modern NAD+ precursors in the healthy aging space, and other materials in bulk, via material transfer agreements (MTAs) to uncover the full potential of NAD+.
-CERP is leading the industry in promoting and supporting NAD+ research. CERP doesn’t limit material donations to studies that will demonstrate a business benefit to ChromaDex, and supports research outside of the framework for dietary supplements. Research through CERP is primarily independently driven, and ChromaDex only provides protocol recommendations, based upon non-public expertise, to improve the likelihood of success. ChromaDex does not alter or influence data analysis, data interpretation, or publication rights.
-In addition to receiving material donations thoroughly tested by the ChromaDex QA & QC teams via MTA for research, these investigators receive additional benefits through CERP including receiving technical support to help improve the likelihood of success of their research, and MTA language that encourages the investigator and institution to develop and own intellectual property.
-CERP has proven to be beneficial to all researchers and product developers in the NAD+ space, including direct competitors, but research from the program has demonstrated that NAD+ supplementation promotes cellular health and may be beneficial to vulnerable health populations. Recent clinical research advances through CERP have demonstrated significantly lower NAD+ levels in age-related conditions including heart disease, Parkinson’s disease, ataxia telangiectasia (AT), autoimmune disorders, and others, while demonstrating NAD-boosting benefits following supplementation with Niagen. This body of research is still growing, and further investigation is needed to determine to what extent Niagen supplementation affects these health outcomes.
-In January 2022, CERP celebrated its 100th published peer-reviewed study on the company’s flagship ingredient Niagen and other materials.
-In Apri 2022, ChromaDex announced the achievement of its 250th external research agreement.
-== Partnerships and joint ventures ==
-In June 2022, ChromaDex signed distribution agreement with Sinopharm Xingsha to accelerate cross-border sales of Tru Niagen into mainland China, and in November 2022 the company announced an agreement to launch a joint venture (JV) in the same territory. China’s marketplace can benefit greatly from Tru Niagen, with more than 260 million people over the age of 60.
-A new partnership with MyPharma2Go was formed to conduct cross-border sales of [https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fsaudecelular.com.br%2F&esheet=52846351&newsitemid=20220901005053&lan=en-US&anchor=Tru+Niagen&index=1&md5=c3e5cabf7e6919d99c625d79e4632f7b Tru Niagen in Brazil]—the first Latin American country to welcome the brand.
-ChromaDex announced a new supply agreement with Designs for Health, a U.S.-based manufacturer of premium dietary supplements for healthcare practitioners (HCPs).
-ChromaDex and Nestlé Health Science announced a new Niagen commercial supply agreement and $5 million investment.
-In 2022, ChromaDex launched a Tru Niagen partnership with ShopHQ, a multiplatform interactive television network with live TV programming that reaches roughly 90 million U.S. homes, and influencer Danny Seo, an authoritative voice on living a healthy, natural, good-for-you life.
-In 2022, ChromaDex partnered with Juvenis for cross-border sales of Tru Niagen into South Korea.
-In 2018, ChromaDex announced a Tru Niagen partnership with Watsons, the leading health and beauty retailer in Asia and Europe.
-In 2021, Tru Niagen launched in 3,800 Walmart stores across the United States.
-In 2021, ChromaDex and Health & Happiness (H&H) Group announced a supply agreement for Niagen, in which H&H Group expanded the Swisse® healthy aging product line into the growing NAD+ space with Niagen.
-== Awards ==
-[https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.nutraingredients.com%2F&esheet=52721219&newsitemid=20220517005235&lan=en-US&anchor=NutraIngredients&index=1&md5=c46641563d3ede676d5eb2ab96e389df NutraIngredients], a leading news source for the nutrition industry, recently honored the ChromaDex External Research Program (CERP) with a [https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.nutraingredients.com%2FArticle%2F2022%2F04%2F04%2FDate-for-the-diary-NutraIngredients-Award-winners-of-2022-to-be-revealed-on-4-May&esheet=52721219&newsitemid=20220517005235&lan=en-US&anchor=2022+European+NutraIngredients+Award&index=3&md5=24ba5f3e153cecc42724e07318b51c43 2022 European NutraIngredients Award] in the “Nutrition Research Project” category for developing the science behind patented Niagen. In 2019, NutraIngredients awarded Tru Niagen the Ingredient of the Year award in the Healthy Aging category.
-Tru Niagen is one of Amazon U.S.’s top-selling brands in the vitamin B3 category for boosting NAD<sup>+</sup> levels as of December 2022.
 ==References==
-{{Reflist|33em}}
+{{Reflist}}
 ==External links==
 * {{Official website|http://www.chromaDex.com}}
+{{Authority control}}
 [[Category:Biotechnology companies of the United States]]